Fennec Pharmaceuticals Inc. (FENC) News
Filter FENC News Items
FENC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
FENC News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest FENC News From Around the Web
Below are the latest news stories about FENNEC PHARMACEUTICALS INC that investors may wish to consider to help them evaluate FENC as an investment opportunity.
Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales~ PEDMARQSI® (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children and young people (1 month-17 years of age) ~ ~ Data from two open-label, randomized Phase 3 trials, SIOPEL 6 (pivotal) and the Clinical Oncology Group (COG) Protocol ACCL0431, demonstrated an approximate 50% reduction in the occurrence of cisplatin-induced ototoxicity in patients treated with cisplatin an |
Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management~ $13 Million Convertible Debt Repayment from Available Cash ~ ~ Elimination of Approximately $1.5 Million in Annual Interest Expense and Potential Equity Overhang of Approximately 1.6 Million Shares ~ RESEARCH TRIANGLE PARK, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced the early repayment of $13 million of the Company’s approximately $32 million outstanding convertible debt facility with Petricho |
Fennec Pharmaceuticals to Participate in Upcoming Investor ConferenceRESEARCH TRIANGLE PARK, N.C., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the virtual H.C. Wainwright @ Home Fireside Chat Series taking place on Monday, December 16, 2024 at 11:00 a.m. ET. To access the live webcast, please visit: https://investors.fennecpharma.com/events-and-presentations/events. An archived replay of the webcast will be avai |
Fennec Pharmaceuticals Third Quarter 2024 Earnings: Misses ExpectationsFennec Pharmaceuticals ( NASDAQ:FENC ) Third Quarter 2024 Results Key Financial Results Revenue: US$6.97m (up 7.0% from... |
Fennec Pharmaceuticals Inc (FENC) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...Fennec Pharmaceuticals Inc (FENC) reports increased sales and strategic initiatives, despite rising expenses and ongoing litigation challenges. |
Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARK ~ ~ Strengthened Executive Leadership Team with Chief Medical Officer, Chief Commercial Officer & Chief Strategy Officer Appointments ~ ~ Company Has Approximately $40 Million in Cash, Cash Equivalents, and Investment Securities Expected to Fund O |
Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. Management will host a conference call and webcast that day to discuss the Company’s financial and business results. Conference Call & Webcast Detail: Date:Thursd |
Individual investors account for 31% of Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) ownership, while hedge funds account for 30%Key Insights The considerable ownership by individual investors in Fennec Pharmaceuticals indicates that they... |
Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company’s Next Stage of Growth~ Pierre S. Sayad, PhD, M.S., Appointed Chief Medical Officer ~ ~ Terry Evans Appointed Chief Commercial Officer ~ ~ Christiana Cioffi, MBA, Appointed Chief Strategy Officer ~ RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that it has strengthened its executive leadership team with the appointments of Pierre S. Sayad, PhD, M.S., as chief medical officer, Ter |
The past three years for Fennec Pharmaceuticals (NASDAQ:FENC) investors has not been profitableIn order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market... |